SCHEMBL3133528

SCHEMBL3133528

CC(C)Oc1cc(N(Cc2cccnc2)c2cccc(C(=O)O)c2)ccc1OC(F)F

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 10/20 0.44
PDE4B Q07343 2/20 0.42
LMNA P02545 2/20 0.41
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
PDE4A P27815 1/20 0.40
PDE4C Q08493 1/20 0.40
PDE4D Q08499 1/20 0.40
RXRA P19793 2/20 0.40
RXRB P28702 1/20 0.40
RXRG P48443 1/20 0.40
POLB P06746 2/20 0.39
MAPT P10636 1/20 0.39
KMO O15229 1/20 0.38
MRGPRX4 Q96LA9 1/20 0.38
DHODH Q02127 1/20 0.38
HPGD P15428 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3133553 0.97 RXRA (0.44) GRM2PDE4BLMNAKMT2AMEN1
SCHEMBL1159028 0.95 GRM2 (0.44) GRM2PDE4BLMNAKMT2APDE4A
SCHEMBL3121497 0.93 RXRA (0.48) GRM2PDE4BLMNAKMT2AMEN1
SCHEMBL3200102 0.92 PDE4B (0.45) GRM2PDE4BLMNAKMT2APDE4A
SCHEMBL4190635 0.91 GRM2 (0.44) GRM2PDE4BLMNAKMT2AMEN1
SCHEMBL3117619 0.91 RXRA (0.41) GRM2PDE4BPDE4APDE4CPDE4D
SCHEMBL3132076 0.90 GRM2 (0.44) GRM2PDE4BLMNAKMT2APDE4A
SCHEMBL3133561 0.90 GRM2 (0.42) GRM2PDE4BLMNAKMT2AMEN1
SCHEMBL3126155 0.89 GRM2 (0.43) GRM2PDE4BLMNAKMT2AMEN1
SCHEMBL3132285 0.89 GRM2 (0.43) GRM2PDE4BLMNAKMT2APDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US claimed
WO-2010003084-A2 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-01-07 WO claimed
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US disclosed
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US disclosed
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US disclosed
WO-2010003084-A2 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-01-07 WO disclosed
WO-2010003084-A2 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS PDE4A, PDE4B, PDE3B GRM2 3498/4885PDE4B 2/4885LMNA 3769/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.